1. Antibody treatment in multiple myeloma.
- Author
-
Maples KT, Johnson C, and Lonial S
- Subjects
- ADP-ribosyl Cyclase 1 antagonists & inhibitors, ADP-ribosyl Cyclase 1 immunology, Animals, Antibodies, Bispecific adverse effects, Antibodies, Bispecific immunology, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological immunology, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Humans, Immunoconjugates adverse effects, Immunoconjugates immunology, Multiple Myeloma immunology, Signaling Lymphocytic Activation Molecule Family antagonists & inhibitors, Signaling Lymphocytic Activation Molecule Family immunology, Antibodies, Bispecific therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Immunoconjugates therapeutic use, Multiple Myeloma drug therapy
- Abstract
Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved. BCMA-targeted antibody-drug conjugates and bispecific antibodies, which are the newest antibody therapies to be investigated, provide additional therapeutic options for patients with heavily pretreated MM. This article reviews how antibody therapy has influenced the treatment of MM, describes the unique adverse event profiles of each relevant drug class, and explains how to incorporate antibody therapy into practice.
- Published
- 2021